We developed a 384-well device and automated workflows that require 5x fewer cells (the largest expense with competing fat cell experimental models). Manufacturing can be scaled further, which is actively under development.

The library used for initial screening contained ~500 compounds. MelliCell would like to add significantly more compounds and potentially include other structures such as large molecules (oligonucleotides). A to add to the library, and 2) improving MelliCell’s digital platform to improve scalability portion of the proceeds generated from the Series A round will be directed towards 1) Acquiring more compounds and automating the analysis of various data sets.

Here is a link to our published PCT. Also see “MelliCell’s IP Strategy” slide.

Based on interest from pharma partners, we expect to have options for acquisition. We are also prepared to go all the way through commercialization if it is the best path for getting our products to patients.

We will selectively engage Pharma partners to validate our technology, bring in additional expertise and resources, and to develop relationships with potential investors and acquirers. A key focus is protecting the IP around our platform and leads and accelerating development of our leads.

We have active agreements with Novo Nordisk and Boehringer Ingelheim. The arrangements have ranged from us retaining ownership of all data to the partner having an exclusive 6-month option to the data, to the partner owning the data (for data on a partner’s lead/target).

In the 50-year history of lab-grown fat, several have tried. MelliCell invented breakthrough technology that enables this for the first time. The timing is right with insurance coverage, disease understanding and awareness. We also have the passion and commitment needed for real world impact.

Our mission is to deliver therapeutics to patients. Our technology is a competitive advantage toward that end.

The percentage decrease in fat cell volume on our platform has a direct corollary with whole body fat loss in patients. There is clear potential to exceed standard of care (~20% weight loss in 1.5 years).

Wegovy and Mounjaro are great examples of what to expect in terms of regulatory and payer requirements.

Any disease that is associated with obesity (e.g. diabetes, high cholesterol, PCOS, NASH, breast and other cancers, COVID, etc.) is relevant to our platform.

In its current form, the platform does not include interactions with nerves, vasculature, or immune cells. Platform development to include some of these other cell types is of interest to pharma partners and is in progress.